A Comparison between SARS-CoV-2 and Gram-Negative Bacteria-Induced Hyperinflammation and Sepsis.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

COVID-19*/complications ; Sepsis*/metabolism; Humans ; Aged ; SARS-CoV-2/metabolism ; Lipopolysaccharides ; Toll-Like Receptor 4/metabolism ; Endotoxins ; Inflammation/complications ; Gram-Negative Bacteria/metabolism ; Cytokines/metabolism ; Anti-Bacterial Agents

Sepsis is a life-threatening condition caused by the body's overwhelming response to an infection, such as pneumonia or urinary tract infection. It occurs when the immune system releases cytokines into the bloodstream, triggering widespread inflammation. If not treated, it can lead to organ failure and death. Unfortunately, sepsis has a high mortality rate, with studies reporting rates ranging from 20% to over 50%, depending on the severity and promptness of treatment. According to the World Health Organization (WHO), the annual death toll in the world is about 11 million. One of the main toxins responsible for inflammation induction are lipopolysaccharides (LPS, endotoxin) from Gram-negative bacteria, which rank among the most potent immunostimulants found in nature. Antibiotics are consistently prescribed as a part of anti-sepsis-therapy. However, antibiotic therapy (i) is increasingly ineffective due to resistance development and (ii) most antibiotics are unable to bind and neutralize LPS, a prerequisite to inhibit the interaction of endotoxin with its cellular receptor complex, namely Toll-like receptor 4 (TLR4)/MD-2, responsible for the intracellular cascade leading to pro-inflammatory cytokine secretion. The pandemic virus SARS-CoV-2 has infected hundreds of millions of humans worldwide since its emergence in 2019. The COVID-19 (Coronavirus disease-19) caused by this virus is associated with high lethality, particularly for elderly and immunocompromised people. As of August 2023, nearly 7 million deaths were reported worldwide due to this disease. According to some reported studies, upregulation of TLR4 and the subsequent inflammatory signaling detected in COVID-19 patients "mimics bacterial sepsis". Furthermore, the immune response to SARS-CoV-2 was described by others as "mirror image of sepsis". Similarly, the cytokine profile in sera from severe COVID-19 patients was very similar to those suffering from the acute respiratory distress syndrome (ARDS) and sepsis. Finally, the severe COVID-19 infection is frequently accompanied by bacterial co-infections, as well as by the presence of significant LPS concentrations. In the present review, we will analyze similarities and differences between COVID-19 and sepsis at the pathophysiological, epidemiological, and molecular levels.

Dent J (Basel). 2023 Jun 19;11(6):. (PMID: 37366677)
Appl Microbiol Biotechnol. 2020 Sep;104(18):7777-7785. (PMID: 32780290)
Anaesth Crit Care Pain Med. 2020 Jun;39(3):385. (PMID: 32499129)
Pediatr Res. 1993 Oct;34(4):471-7. (PMID: 8255680)
Immunotherapy. 2013 Mar;5(3):207-9. (PMID: 23444949)
EBioMedicine. 2022 Dec;86:104355. (PMID: 36470836)
Lancet Respir Med. 2020 Oct;8(10):946-949. (PMID: 32444269)
Biol Chem. 2001 Aug;382(8):1215-25. (PMID: 11592403)
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620938149. (PMID: 32677459)
ACS Pharmacol Transl Sci. 2020 Jun 16;3(4):780-782. (PMID: 32821884)
Resuscitation. 2021 Feb;159:150-157. (PMID: 33176170)
JCI Insight. 2020 Sep 3;5(17):. (PMID: 32687484)
FEBS Lett. 2022 Oct;596(19):2566-2575. (PMID: 36050806)
Exp Mol Med. 2017 Jun 16;49(6):e345. (PMID: 28620220)
Cerebrovasc Dis. 2021;50(2):132-140. (PMID: 33530081)
ACS Pharmacol Transl Sci. 2022 Jan 25;5(3):141-148. (PMID: 35774232)
Pathogens. 2020 Oct 15;9(10):. (PMID: 33076482)
Best Pract Res Clin Haematol. 2022 Sep;35(3):101401. (PMID: 36494149)
Blood Rev. 2021 May;47:100761. (PMID: 33067035)
N Engl J Med. 2020 Jul 9;383(2):120-128. (PMID: 32437596)
Gastroenterology. 1978 Sep;75(3):532-5. (PMID: 680522)
Am J Hematol. 2020 Jul;95(7):834-847. (PMID: 32282949)
Expert Rev Anti Infect Ther. 2021 Apr;19(4):495-517. (PMID: 33210958)
Curr Genomics. 2021 Dec 30;22(5):339-352. (PMID: 35283665)
Biophys J. 2007 Apr 15;92(8):2796-805. (PMID: 17237210)
Int J Mol Sci. 2021 Jun 01;22(11):. (PMID: 34205975)
Signal Transduct Target Ther. 2022 Jul 7;7(1):220. (PMID: 35798699)
Eur J Biochem. 2000 Apr;267(7):2008-13. (PMID: 10727940)
Ann Intensive Care. 2023 Mar 12;13(1):17. (PMID: 36906875)
Pathogens. 2022 Jul 31;11(8):. (PMID: 36014988)
J Mol Cell Biol. 2021 Mar 10;12(12):916-932. (PMID: 33295606)
Front Immunol. 2023 Feb 09;14:1126874. (PMID: 36845110)
Cytokine. 2021 Dec;148:155628. (PMID: 34411989)
J Clin Invest. 2022 Feb 1;132(3):. (PMID: 34871182)
Front Public Health. 2022 Feb 11;10:833967. (PMID: 35223745)
Trends Microbiol. 2021 Oct;29(10):930-941. (PMID: 33934980)
Sci Rep. 2022 Sep 20;12(1):15703. (PMID: 36127433)
Lancet. 2021 Jul 17;398(10296):223-237. (PMID: 34274064)
J Microbiol Immunol Infect. 2020 Aug;53(4):505-512. (PMID: 32482366)
Biophys J. 1993 Apr;64(4):1215-31. (PMID: 8494979)
Eur J Biochem. 2004 May;271(10):2037-46. (PMID: 15128313)
BMJ. 2020 Jul 22;370:m2935. (PMID: 32699011)
Infez Med. 2021 Mar 1;29(1):20-36. (PMID: 33664170)
Syst Rev. 2023 May 27;12(1):88. (PMID: 37245047)
Chem Immunol. 2000;74:42-60. (PMID: 10608081)
Semin Immunopathol. 2017 Jul;39(5):517-528. (PMID: 28555385)
JCI Insight. 2020 Sep 3;5(17):. (PMID: 32706339)
Biophys J. 2011 Jun 8;100(11):2652-61. (PMID: 21641310)
JCI Insight. 2018 Mar 8;3(5):. (PMID: 29515037)
J Leukoc Biol. 2022 Feb;111(2):489-496. (PMID: 33909917)
Pharmacol Ther. 1981;15(3):383-402. (PMID: 6179107)
Innate Immun. 2011 Oct;17(5):427-38. (PMID: 20682588)
Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307)
Curr Top Microbiol Immunol. 1996;216:39-81. (PMID: 8791735)
Acta Biomed. 2020 Mar 19;91(1):157-160. (PMID: 32191675)
Emerg Microbes Infect. 2021 Dec;10(1):317-330. (PMID: 33560940)
Front Immunol. 2021 Jun 21;12:677008. (PMID: 34234779)
Int Immunopharmacol. 2021 Nov;100:108125. (PMID: 34543980)
Drugs. 2023 Jan;83(1):1-36. (PMID: 36508116)
Antimicrob Agents Chemother. 2010 Sep;54(9):3817-24. (PMID: 20606063)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Signal Transduct Target Ther. 2021 Jan 1;6(1):1. (PMID: 33384407)
IUBMB Life. 2020 Oct;72(10):2097-2111. (PMID: 32770825)
Intern Emerg Med. 2022 Mar;17(2):515-524. (PMID: 33914228)
J Biol Chem. 1995 May 5;270(18):10482-8. (PMID: 7537731)
Appl Microbiol Biotechnol. 2011 May;90(3):799-808. (PMID: 21369803)
Cell Mol Immunol. 2020 May;17(5):541-543. (PMID: 32203186)
Sci Rep. 2015 Sep 22;5:14292. (PMID: 26390973)
Front Immunol. 2020 Nov 30;11:598404. (PMID: 33329592)
Crit Care. 2020 Sep 4;24(1):549. (PMID: 32887652)
Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R759-66. (PMID: 15205185)
Front Immunol. 2021 Jul 19;12:701275. (PMID: 34349763)
Front Immunol. 2021 Jan 28;11:621441. (PMID: 33584719)
Nat Med. 2021 Apr;27(4):601-615. (PMID: 33753937)
Inflammopharmacology. 2023 Apr;31(2):551-557. (PMID: 36964860)
Vaccines (Basel). 2023 Feb 13;11(2):. (PMID: 36851312)
J Korean Med Sci. 2020 Sep 28;35(38):e343. (PMID: 32989935)
Eur Respir Rev. 2020 Oct 1;29(157):. (PMID: 33004529)
Sci Rep. 2023 Jul 11;13(1):11207. (PMID: 37433819)
J Clin Med. 2020 Dec 15;9(12):. (PMID: 33334050)
Front Public Health. 2022 Aug 16;10:923485. (PMID: 36052001)
J Endotoxin Res. 2006;12(5):261-77. (PMID: 17059690)
Medicine (Baltimore). 2021 Mar 26;100(12):e24971. (PMID: 33761654)
J Biol Chem. 2004 Jun 18;279(25):26307-13. (PMID: 15096514)

CNE-2022-104/1-1 C.N. Phospholipid Research Center

Keywords: ARDS; Aspidasept; COVID-19 pandemic; Gram-negative bacteria; TLR4; cytokines; hyperinflammation; lipopolysaccharide; sepsis

0 (Lipopolysaccharides)
0 (Toll-Like Receptor 4)
0 (Endotoxins)
0 (Cytokines)
0 (Anti-Bacterial Agents)

Date Created: 20231028 Date Completed: 20231030 Latest Revision: 20231030

20231215

PMC10607443

10.3390/ijms242015169

37894850